Literature DB >> 10908910

Disease progression in sporadic inclusion body myositis: observations in 78 patients.

A Peng1, B M Koffman, J D Malley, M C Dalakas.   

Abstract

Functional decline for each decade at symptom onset and need for cane, walker, or wheelchair were assessed in 78 biopsy-proved patients with sporadic inclusion body myositis. Patients with disease onset between 40 and 59 years used a walker after 10.2 +/- 5.8 years, whereas those with disease onset between 60 and 79 years used a walker after 5.7 +/- 5.0 years (p = 0.05). Because patients progress faster to disability when symptoms begin after the age of 60, age at disease onset may define patient subsets for stratification in clinical trials.

Entities:  

Mesh:

Year:  2000        PMID: 10908910     DOI: 10.1212/wnl.55.2.296

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Diagnosis and treatment of inflammatory muscle diseases.

Authors:  David Hilton-Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

2.  Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis.

Authors:  Linda Pax Lowes; Lindsay Alfano; Laurence Viollet; Xiomara Quintero Rosales; Zarife Sahenk; Brian K Kaspar; K Reed Clark; Kevin M Flanigan; Jerry R Mendell; Michael P McDermott
Journal:  Muscle Nerve       Date:  2012-02       Impact factor: 3.217

3.  Disability in idiopathic inflammatory myopathies: questionnaire-based study.

Authors:  Aleksandra Halina Opinc; Olga Elżbieta Brzezińska; Joanna Samanta Makowska
Journal:  Rheumatol Int       Date:  2019-04-26       Impact factor: 2.631

4.  Demographic and clinical features of inclusion body myositis in North America.

Authors:  A David Paltiel; Einar Ingvarsson; Donald K K Lee; Richard L Leff; Richard J Nowak; Kurt D Petschke; Seth Richards-Shubik; Ange Zhou; Martin Shubik; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2015-02-17       Impact factor: 3.217

5.  B7-H1 expression in vestibular schwannomas.

Authors:  David J Archibald; Brian A Neff; Stephen G Voss; Patrick L Splinter; Colin L W Driscoll; Michael J Link; Haidong Dong; Eugene D Kwon
Journal:  Otol Neurotol       Date:  2010-08       Impact factor: 2.311

6.  Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

Authors:  Umesh A Badrising; Marion L C Maat-Schieman; Johannes C van Houwelingen; Peter A van Doorn; Sjoerd G van Duinen; Baziel G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne de Visser; Jan J G M Verschuuren; Axel R Wintzen
Journal:  J Neurol       Date:  2005-06-17       Impact factor: 4.849

Review 7.  Autoimmune Myopathies: Updates on Evaluation and Treatment.

Authors:  Emer R McGrath; Christopher T Doughty; Anthony A Amato
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

8.  Inclusion body myositis: a case of bilateral extremity weakness.

Authors:  Luke Lam; Stephen Scheper; Natalia Zagorski; Mark Chung; Hiroji Noguchi; Kore K Liow
Journal:  Hawaii J Med Public Health       Date:  2013-12

9.  Epidemiology and Natural History of Inclusion Body Myositis: A 40-Year Population-Based Study.

Authors:  Shahar Shelly; Michelle M Mielke; Jay Mandrekar; Margherita Milone; Floranne C Ernste; Elie Naddaf; Teerin Liewluck
Journal:  Neurology       Date:  2021-04-20       Impact factor: 11.800

Review 10.  Autoimmune Neurogenic Dysphagia.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Dysphagia       Date:  2021-07-05       Impact factor: 2.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.